TY - JOUR T1 - Inflammatory Breast Cancer Outcomes in a Contemporary Series JF - Anticancer Research JO - Anticancer Res SP - 5057 LP - 5063 VL - 37 IS - 9 AU - ELIZABETH PAN AU - LILY TUNG AU - OMAR RAGAB AU - ELISE MOROCCO AU - JULIE WECSLER AU - RICHARD SPOSTO AU - AKSHARA RAGHAVENDRA AU - EUGENE CHUNG AU - JULIE E. LANG Y1 - 2017/09/01 UR - http://ar.iiarjournals.org/content/37/9/5057.abstract N2 - Background. Evidence on the management of inflammatory breast cancer (IBC) is limited. This study investigated factors influencing IBC treatment outcomes such as event-free survival (EFS) and overall survival (OS). Materials and Methods: Data were collected from 173 patients with stage III non-IBC and 17 patients with IBC diagnosed at the Keck Medical Center and Los Angeles County and University of Southern California (LAC+USC) Medical Center. Cox proportional hazard regression evaluated associations between variables significant for EFS and OS. Results: On multivariate analysis, negative estrogen receptor (ER)status [hazard ratio (HR)=1.88, 95% confidence interval (CI)=1.11-3.18, p<0.06) and lack of postoperative radiation treatment (HR=2.07, 95% CI=1.03-4.15, p<0.04) were significant for poorer EFS. High Scarff-Bloom-Richardson (SBR) score (HR=2.24, 95% CI=0.79-6.36, p<0.13) and lack of postoperative radiation treatment to the breast (HR=4.39, 95% CI=0.39-49.55, p<0.23) were associated with lower rates of OS. Conclusion: The diagnosis of IBC has a significantly worse prognosis. Receipt of post-mastectomy radiation therapy was a significant predictor of better EFS and OS. ER -